This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, March 19, 2025

A Massachusetts-based biotech company is finding a tremendous amount of success during Wednesday’s session after the company announced a strategic worldwide licensing agreement for its BDTX-4933 for solid tumors.

Traders wasted no time buying up shares of Black Diamond Therapeutics Inc. (Nasdaq:BDTX) following the announcement, pushing the small cap up to $2.78/share (+65.48%) at the early session high. This move could be an indication that this stock is breaking out of the multi-month downtrend it has been stuck in since late summer.

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.